3 questions lodged at 2026 Invion (IVX) virtual EGM
May 30, 2026
Below is the text of the 3 written questions submitted at the Invion (IVX) 4pm AEST virtual EGM on May 29, 2026 to approve 16 transaction and capital raising resolutions including broker options via this Zoom/Vistra link. See notice of meeting. Market cap $4.65m on EGM day. The proxies were not disclosed early as no formal address was lodged with the ASX ahead of commencement. Biggest protest 15.4% against incentive grant to chair Thian Chew. Director and company secretary Melanie Leydin from Vistra was unwell so her colleague Tony Di Pietro ran the meeting. No other shareholder asked questions. Also asked these 4 questions an the EGM called in May 2025.
Q1. You haven't disclosed the proxy votes to the ASX before today's meeting started so could you please do that ahead of future shareholder meetings to allow for a more fully informed debate. Have there been any material proxy protest votes against any of today's 16 resolutions? If so, have any top 10 shareholders informed you why they voted against?
Answer: Need to keep working on Vistra company secretary for hire Tony Di Pietro to get with the program to embrace early proxy disclosure to facilitate better informed debate at AGMs/EGMs. At its heart, the AGM is essentially a vote outcome announcement event. Tony said there were no material protest votes, although you could argue 15.4% against the chair's incentive grant was worth a mention. Watch video of exchange via Twitter.
Q2. For a company with a market cap of just $4.65m, it seems a bit over the top to call a shareholder meeting with a 157 page notice of meeting and 16 items of business. Why are you making this so complex and convoluted? And did we really have to commission this BDO report? How much did it cost shareholders?
Answer: The chair Thian Chew said they were simply following all the rules. Watch video of exchange via Twitter.
Q3. Resolution 6 question: "I'm not a fan of paying brokers and investment bankers with equity because they are not generally long term holders and it gives then an incentive to talk up the stock to clients in order to facilitate a more profitable exit. What is our history with Blue Ocean Equities and whose idea was it to partially pay them via this resolution. Will you commit to not do this again?"
Answer: Invion has wracked up $165m in losses for shareholders developing its next-generation cancer treatment called Photosoft which targets cancers and infectious diseases by using specialized, light-activated compounds that selectively accumulate in diseased cells and destroy them without harming healthy tissues. Watch chair Thian Chew explain why they are dishing equity to brokers like Blue Ocean Equities as part of their latest stay alive capital raising. Don't like these deals as it encourages pump and dump broking. Watch video of exchange via Twitter.
Copyright © 2026 The Mayne Report. All rights reserved
